Outcome of Board Meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Shree Ganesh Remedies Ltd approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with the auditor's limited review report. Revenue from operations fell to ₹2,110.68 lakhs in Q3 FY26 from ₹2,705.28 lakhs in Q3 FY25, a decline of about 22%. For the nine-month period, revenue dropped to ₹7,608.96 lakhs from ₹8,416.06 lakhs. Profit after tax also weakened sharply to ₹309.62 lakhs in Q3 FY26 from ₹543.34 lakhs a year earlier, with 9M FY26 PAT at ₹1,150.11 lakhs versus ₹1,650.10 lakhs. Auditor Chaudhary Shah & Associates LLP issued an unqualified (clean) limited review report on both standalone and consolidated results.
Shareholders should note a clear slowdown in both revenue and profitability versus the prior year, with the Q3 quarter showing steeper declines than the full nine-month trend, suggesting margin pressure and weaker demand. The clean auditor review provides some comfort, but the negative growth trajectory is likely to weigh on short-term sentiment.